Multi-center Registration Study of Adult Onset Still's Disease in Chinese Population

Key facts

Sponsor

Second Xiangya Hospital of Central South University

Principal Investigator

Qianjin Lu, MD，PHD

Central South University

Intervention

Exon sequencing and Methylated sequencing(diagnostic_test)

Enrollment

150 enrolled

Eligibility

18 years · All sexes

Timeline

2018 – 2022

Study locations (1)

• The Second Xiangya Hospital of Central South University, Hunan, Changsha, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult-onset Still disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07203001
  A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
  Novartis Pharmaceuticals
• ACTIVE NOT RECRUITINGPHASE3NCT05814159
  A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
  Swedish Orphan Biovitrum
• RECRUITINGNCT04402086
  Rheumatology Patient Registry and Biorepository
  Yale University
• RECRUITINGNCT03510442
  Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• RECRUITINGNCT05927454
  Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
  Institut National de la Santé Et de la Recherche Médicale, France
• RECRUITINGNCT02143986
  Glycosylated Ferritin in Macrophagic Activation Syndromes
  Brugmann University Hospital

See all trials for Adult-onset Still disease →